News

News & Resources

>

News

· Stay informed with the latest breakthroughs

February 12, 2026

Big Health Secures Funding to Accelerate Adoption of Digital Mental Health Treatments

New investment fuels expansion as leading health systems adopt evidence-based digital care, driven by new billing codes and strong demand for proven mental health solutions.

Landmark Randomized Controlled Trial Demonstrates Efficacy of Daylight™ Digital Therapeutic in Improving Anxiety

71% of Daylight users in the study achieved and maintained remission of Generalized Anxiety Disorder (GAD) by week 10 follow-up, compared to 33% of controls.

Big Health Raises $39 Million in Series B Financing from Gilde Healthcare, Morningside Ventures, Kaiser Permanente Ventures, and Octopus Ventures

Big Health announces $39MM in Series B financing led by Gilde Healthcare and Morningside Ventures; existing investors Kaiser Permanente Ventures & Octopus Ventures.

Digital Therapeutic Sleepio™ Yields 28% Lower Healthcare Costs

A health economic evaluation of Sleepio was conducted at a Fortune 500 company in collaboration with IBM Watson Health. The cohort of Sleepio users had 28% lower healthcare costs.

NHS staff across England get free access to mental health apps Daylight and Sleepio

Big Health and NHS England to provide all staff across England with free access to mental health apps Daylight and Sleepio during the COVID-19 pandemic.

September 20, 2019

Former NHS Medical Director Sir Bruce Keogh Joins Big Health Advisory Board

Former NHS Medical Director Sir Bruce Keogh Joins Big Health Advisory Board

CVS Health Adds Big Health’s Digital Therapeutics for the 24-Hour Problem of Mental Health to Its Point Solutions Management Program

CVS Health today announced that Big Health's 24-hour mental health solution — Sleepio for poor sleep, and Daylight for worry and anxiety — is now available to employers and other plan sponsors through CVS Caremark’s Point Solutions Management program.

BigHealth © 2026 · All rights reserved · Privacy Policy

1. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769–781.
2. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A. J., Emsley, R., Gu, J., Shin, O., Otto, M. W., Craske, M. G., Saunders, K. E. A., Goodwin, G. M., & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate-to-severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and anxiety, 37(12), 1168–1178. https://doi.org/10.1002/da.23079
3. Unpublished RCT data, Dec 2023. Stat reflects a 25% improvement in scores on a validated screening measure. Screening tools alone are not sufficient to diagnose depression.

Sleepio, Daylight, and Spark Direct are digital programs that may help individuals live well with mental health conditions and symptoms by providing them with cognitive and behavioral techniques that can improve sleep, feelings of worry and anxiety, and mood, respectively. Sleepio, Daylight, and Spark Direct have not been reviewed or approved by the Food & Drug Administration and are not intended to diagnose or treat any medical condition. Please read the instructions for use